Skip to main content
HCPCS Q5123 · Level II · Part B drug

Q5123: rituximab-arrx (Riabni), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5123

Billing unit
10 MG
Inj. riabni, 10 mg
ASP payment limit
$21.083
October 2026; +13.8% vs July 2026
Practitioner MUE
150
MAI 3
OPPS status
SI K
APC 9411
NCCI exposure
no PTP pairs
Coverage articles
3
13 states

TL;DR

HCPCS Q5123 is the Level II code for Injection, rituximab-arrx, biosimilar, (riabni), 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $21.083 per billing unit, up 13.8% from July 2026. The practitioner MUE allows up to 150 units per date of service (MAI 3), so a full 150-unit day is $3,162.45 at the current limit. Under OPPS it carries status indicator K in APC 9411. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. Other HCPCS codes whose descriptor names rituximab: Q5119 (biosimilar rituximab-pvvr (Ruxience) from Pfizer Inc); Q5115 (biosimilar rituximab-abbs (Truxima) from Cephalon, LLC); J9312 (non-biosimilar rituximab (Rituxan) from Genentech, Inc). The ASP crosswalk maps 2 NDCs to it, sold as Riabni by Amgen Inc. 3 Medicare coverage articles list the code across 13 states, including A55639.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5123 at $21.083 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $18.533 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q5123
QuarterPayment limitPerCoinsurance
October 2026$21.08310 MG20%
July 2026$18.53310 MG—
CMS note: 8% of reference add-on applied

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to Q5123. Report the NDC in the claim's drug segment and bill the number of Q5123 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to Q5123
NDCDrug nameLabelerPackage sizeBilling units / package
55513-0224-01RiabniAmgen Inc10 × 110
55513-0326-01RiabniAmgen Inc50 × 150

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q5123. For practitioners the limit is 150 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q5123 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services1503 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital1503 Date of Service Edit: ClinicalPrescribing Information

MUE for Q5123 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5123 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5123 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5123 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

3 current Medicare Administrative Contractor articles list Q5123 in their HCPCS tables, covering 13 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing Q5123
ArticleTitleContractor(s)StatesRelated LCD
A55639Billing and Coding: Chemotherapy Agents for Non-Oncologic ConditionsWisconsin Physicians Service Insurance CorporationIA KS MO NEL37205
A56380Billing and Coding: RituximabPalmetto GBANC SC VA WVL35026
A59101Billing and Coding: Off-label Use of Rituximab and Rituximab BiosimilarsWellpoint FederalCT IL MN NY WIL39297

Diagnoses Medicare contractors cover for Q5123

3 billing and coding articles attach a covered diagnosis list to Q5123: 943 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for Q5123
ICD-10-CMDescription (FY2027)Articles covering
D59.0Drug-induced autoimmune hemolytic anemia3 of 3
D59.11Warm autoimmune hemolytic anemia3 of 3
D59.12Cold autoimmune hemolytic anemia3 of 3
D59.13Mixed type autoimmune hemolytic anemia3 of 3
D59.19Other autoimmune hemolytic anemia3 of 3
D68.4Acquired coagulation factor deficiency3 of 3
D69.3Immune thrombocytopenic purpura3 of 3
D69.41Evans syndrome3 of 3
D69.42Congenital and hereditary thrombocytopenia purpura3 of 3
D69.49Other primary thrombocytopenia3 of 3
G35.ARelapsing-remitting multiple sclerosis3 of 3
G36.0Neuromyelitis optica [Devic]3 of 3
G61.81Chronic inflammatory demyelinating polyneuritis3 of 3
G70.00Myasthenia gravis without (acute) exacerbation3 of 3
G70.01Myasthenia gravis with (acute) exacerbation3 of 3
928 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q5123 are counted here: a group whose instructions name Q5123, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to Q5123, by article
ArticleContractorGroups that applyCovered codes for Q5123Full list
A55639Wisconsin Physicians Service Insurance Corporation6 groups apply to Q5123309On LCD L37205
A56380Palmetto GBAgroups 1 and 2 apply to Q5123692On LCD L35026
A59101Wellpoint Federalone list for every code in the article836On LCD L39297

Local coverage policies that list Q5123

3 active Local Coverage Determinations list Q5123 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5123 carries status indicator K and is assigned to APC 9411, with a published national unadjusted payment of $21.083. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5123 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $21.08 per 10 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5123 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5123

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5123

What does HCPCS code Q5123 describe?

Q5123 is defined by CMS as "Injection, rituximab-arrx, biosimilar, (riabni), 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5123 a CPT code?

No. Q5123 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as rituximab-arrx (Riabni); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5123 reports the drug itself in 10 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5123 in October 2026?

The ASP-based payment limit is $21.083 per 10 MG, with 20% beneficiary coinsurance. The July 2026 limit was $18.533. Commercial payers use their own fee schedules.

How many units of Q5123 can be billed per day?

The practitioner Medically Unlikely Edit is 150 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q5123?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Riabni (Amgen Inc). For example NDC 55513-0224-01 (package size 10) equals 10 billing units of Q5123.

Does Q5123 have NCCI bundling edits?

No active practitioner PTP pairs list Q5123 as a column-1 or column-2 code in the v323r0 release.

Q5123 vs Q5119: what is the difference?

Both are HCPCS Level II codes whose descriptor names rituximab. What sets Q5119 apart: biosimilar rituximab-pvvr (Ruxience) from Pfizer Inc. Q5123 is billed per 10 mg, limit $21.083, MUE 150; Q5119 is billed per 10 mg, limit $5.792, MUE 150. Report the code whose descriptor matches the product and setting in the record.

Q5123 vs Q5115: what is the difference?

Both are HCPCS Level II codes whose descriptor names rituximab. What sets Q5115 apart: biosimilar rituximab-abbs (Truxima) from Cephalon, LLC. Q5123 is billed per 10 mg, limit $21.083, MUE 150; Q5115 is billed per 10 mg, limit $35.988, MUE 150. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention Q5123?

3 current Billing and Coding Articles in the Medicare Coverage Database list Q5123, covering 13 states: A55639 (Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions); A56380 (Billing and Coding: Rituximab); A59101 (Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars).

What diagnosis codes support Q5123?

3 Medicare billing and coding articles list 943 covered ICD-10-CM codes for Q5123 between them, for example D59.0 (Drug-induced autoimmune hemolytic anemia); D59.11 (Warm autoimmune hemolytic anemia); D59.12 (Cold autoimmune hemolytic anemia); D59.13 (Mixed type autoimmune hemolytic anemia); D59.19 (Other autoimmune hemolytic anemia). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.